Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophreniaKonrad Talbot, Steven E. Arnold|Journal of Clinical Investigation|2004Cited by 412
Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseasesElizabeth M. Rhea, Konrad Talbot, P. C. Thomas et al.|Tissue Barriers|2023Cited by 68